The narrative around pattern hair loss treatments is shifting from hormonal interventions to non-hormonal and regenerative approaches, reflecting broader trends in medical innovation. VeraDermics’ VDPHL01 stands out as a potential game-changer, offering an oral alternative to topical minoxidil with reduced cardiac risks. The phase 2/3 trial results are robust, but long-term safety and efficacy data will be critical, especially given minoxidil’s history of cardiovascular side effects. Pelage Phar...